NCT07436988 2026-03-12
ReLIVE
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 1 Not yet recruiting
Clinical Trials
78 trialsNCT03028311 2026-03-10
Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT07430202 2026-02-24
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Not yet recruiting
NCT07148050 2026-02-17
IMPACT
Seattle Children's Hospital
Phase 1 Recruiting
NCT04377932 2026-01-21
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Baylor College of Medicine
Phase 1 Active not recruiting
NCT05155189 2026-01-21
A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
Zhejiang University
Phase 1 Recruiting
NCT04658147 2025-12-18
Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT02869217 2025-12-03
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
University Health Network, Toronto
Phase 1 Active not recruiting
NCT05427396 2025-12-03
A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Terminated
NCT07224568 2025-11-04
INTERCEPT
Seattle Children's Hospital
Phase 1 Not yet recruiting
NCT02932956 2025-09-19
GAP
Baylor College of Medicine
Phase 1 Active not recruiting
NCT06533332 2025-09-18
A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
EtiraRx Australia Pty Ltd
Phase 1 Recruiting
NCT05701488 2025-09-02
SIRT With Tremelimumab and Durvalumab for Resectable HCC
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT06084299 2025-08-19
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver Cancer
Tongji Hospital
Phase 1 Recruiting
NCT07001592 2025-06-03
RIOT3
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Phase 1 Recruiting
NCT06673329 2025-05-14
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
Phase 1 Recruiting
NCT04715191 2025-05-02
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Baylor College of Medicine
Phase 1 Recruiting
NCT03253289 2024-10-02
OPTIM
Baylor College of Medicine
Phase 1 Completed
NCT03299946 2024-09-03
Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT06196294 2024-06-26
GPC3/Mesothelin-CAR-γδT Cells Against Cancers
Second Affiliated Hospital of Guangzhou Medical University
Phase 1 Recruiting
NCT04842812 2024-06-25
Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
Phase 1 Recruiting
NCT05829057 2024-02-13
The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1
Zhejiang University
Phase 1 Unknown
NCT00486356 2024-01-03
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
University of Nebraska
Phase 1 Completed
NCT06006338 2023-09-21
3D Printed Models for Liver Surgery
Zhejiang Cancer Hospital
Phase 1 Unknown
NCT05510427 2023-08-15
Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT02094625 2023-04-18
NAC to Prevent Cisplatin-induced Hearing Loss
Children's Hospital Los Angeles
Phase 1 Completed
NCT05738447 2023-02-22
Application of mRNA Immunotherapy Technology in Hepatitis B Virus-related Refractory Hepatocellular Carcinoma
West China Hospital
Phase 1 Unknown
NCT05643417 2022-12-08
Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard Therapy
Fudan University
Phase 1 Unknown
NCT05093608 2022-10-17
SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Terminated
NCT01525069 2022-08-10
Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma
Washington University School of Medicine
Phase 1 Terminated
NCT05240950 2022-03-11
Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases
Changhai Hospital
Phase 1 Recruiting
NCT05240690 2022-02-15
Umbilical Cord Blood Derived MAK Immune Cells Combined With Standard Second-Line Treatments for Hepatobiliary and Pancreatic Malignancies
Zhongnan Hospital
Phase 1 Unknown
NCT02292173 2021-06-10
Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02893982 2021-05-18
High Dose Rate Brachyablation of Primary Liver Lesions
University of Texas Southwestern Medical Center
Phase 1 Terminated
NCT02753881 2020-08-03
Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer
Yale University
Phase 1 Completed
NCT01099631 2020-07-20
IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT02989870 2020-06-05
Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Withdrawn
NCT00007813 2020-02-17
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT01497444 2020-02-06
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Alliance for Clinical Trials in Oncology
Phase 1 Completed
NCT03159585 2020-01-22
To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors
Zhujiang Hospital
Phase 1 Completed
NCT02288507 2019-11-08
Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
University of Hawaii
Phase 1 Withdrawn
NCT03993743 2019-08-28
A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma
Xijing Hospital
Phase 1 Unknown
NCT01008917 2019-05-09
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
University of California, San Francisco
Phase 1 Completed
NCT02145559 2019-04-22
A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
University of Chicago
Phase 1 Completed
NCT02151864 2019-03-05
LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis
University of California, San Diego
Phase 1 Completed
NCT01469572 2018-10-18
Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases
Emory University
Phase 1 Completed
NCT03674073 2018-10-18
A Study Combining Personalized Neoantigen-based Dendritic Cell Vaccine With Microwave Ablation for the Treatment of Hepatocellular Carcinoma
Chinese PLA General Hospital
Phase 1 Unknown
NCT01665937 2018-04-25
STA-9090 in Patients With Advanced Hepatocellular Cancer
Massachusetts General Hospital
Phase 1 Completed
NCT01744054 2018-03-05
Microsphere Localization Using PET/MRI or PET/CT in Patients Following Radioembolization
Washington University School of Medicine
Phase 1 Terminated
NCT01011010 2018-01-05
Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed